SOUTH SAN FRANCISCO — February 13, 2019 — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that Bernard Coulie, M.D., Ph.D., president and chief executive officer, will present an update on the company and its programs at two upcoming healthcare investor conferences.
SVB Leerink Global Healthcare Conference
Date & Location: Wednesday, February 27, 2019, New York City
Presentation Time: 1:50 p.m. – 2:10 p.m. EST
Cowen’s 39th Annual Health Care Conference
Date & Location: Tuesday, March 12, 2019, Boston
Presentation Time: 9:30 a.m. – 9:55 a.m. EDT
About Pliant Therapeutics
Pliant Therapeutics is a biotechnology company unraveling and targeting the key biological pathways driving fibrosis. By leveraging its powerful product discovery engine, Pliant’s mission is to develop novel therapeutics that seek to halt progression of fibrotic diseases, ultimately preserving organ function. Founded by a group of seasoned experts in fibrosis biology, medicinal chemistry and translational medicine, Pliant expects to initiate clinical trials with its lead product candidate PLN-74809 in idiopathic pulmonary fibrosis in late 2018, with additional programs to advance into the clinic in 2019. For more information, please visit www.pliantrx.com.